The pharmaceutical company posted adjusted earnings of $1.08 per share for Q3 2025, handily beating the analyst consensus of $0.74. Revenue surged to $239.5 million, representing 29% YoY growth and ...

Two stocks stand out for contracted megawatt capacity rather than speculative buildouts: a purpose-built campus operator with 15-year leases and fixed minimum payments from hyperscalers, and an ...